Olmesartan Ratiopharm (Olmesartan Medoxomil)

Olmesartan medoxil, the active ingredient in Olmesartan Ratiopharm, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Olmesartan Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Ratiopharm is an ARB that lowers blood pressure by acting on the renin‑angiotensin system.

- Hypertension: helps reduce systolic and diastolic blood pressure in adults. - Heart failure: used as part of combination therapy to improve cardiac output and symptoms. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes.

Olmesartan Ratiopharm may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea

Serious or Rare Side Effects: - Angio‑ema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation (transaminases)

When prescribing Olmesartan Ratiopharm, clinicians should consider several safety aspects.

- Renal function: assess baseline renal function and monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially in patients on diuretics. - Pregnancy: contraindicated in the second and ​  ​  ​   ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​​ - Concomitant NSAIDs: increased risk of renal impairment. - Hyperkalemia risk: avoid use with potassium‑sparing diuretics or supplements. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Olmesartan Ratiopharm can interact with several medicines that affect blood pressure, renal function, or electrolyte balance.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients may increase risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium. - Lithium: concurrent use can raise lithium levels, risking toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihyol    -     t   t  \